

PRIOR AUTHORIZATION REQUEST FORM

Antiretrovirals

Aptivus, Complera, Edurant, efavirenz/lamivudine/tenofovir, emtricitabine/rilpivirine/tenofovir, Emtriva, Epivir, fosamprenavir, Fuzeon, Intelence, Juluca, Kaletra, Norvir tablet, Odefsey, Pifeltro, Retrovir, Reyataz capsule, Selzentry tablet, Stribild, Symtuza, Trogarzo, Truvada, Viracept, Viread 300mg, Vocabria, Ziagen solution

For authorization, please answer each question and fax this form PLUS chart notes back to RealRx Medicaid Prior Authorization Department at 385-425-4052.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If you have prior authorization questions, please call Pharmacy Customer Service for assistance.

- Healthy U: 855-856-5694
- Healthy U CHIP: 855-203-3633
- Health Choice Utah: 855-864-1404

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:

Height/Weight:

Combination Products:

Preferred: abacavir/lamivudine, Biktarvy, Cabenuva*, Cimduo, Delstrigo, Descovy, Dovato, efavirenz/emtricitabine/tenofovir, emtricitabine/tenofovir, Evotaz, Genvoya, lamivudine/zidovudine, lopinavir/ritonavir, Prezcoibx, Symfi, Symfi Lo, Triumeq

Non-preferred: Complera, efavirenz/lamivudine/tenofovir, emtricitabine/rilpivirine/tenofovir, Juluca, Kaletra, Odefsey, Stribild, Sunlenca*, Symtuza, Truvada, Yeztugo*

*see drug specific prior authorization criteria form

Entry, Fusion Inhibitors

Preferred Products: maraviroc, Selzentry solution

Non-preferred Products: Fuzeon, Rukobia*, Selzentry tablet, Trogarzo

*see drug specific prior authorization criteria form

Integrase Inhibitors

Preferred: Apretude, Isentress, Tivicay

Non-preferred: Vocabria

Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs):

Preferred: efavirenz, etravirine, nevirapine

Non-preferred: Edurant, Intelence, Pifeltro

Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs):

Preferred: abacavir solution, abacavir tablet, emtricitabine, lamivudine, tenofovir disoproxil 300mg, Viread (all except 300mg), zidovudine

Non-preferred: Emtriva, Epivir, Retrovir, Viread 300mg, Ziagen solution

Protease Inhibitors

Preferred: atazanavir capsule, darunavir, Norvir powder, Prezista, Reyataz powder, ritonavir tablet

Non-preferred: Aptivus, fosamprenavir, Norvir tablet, Reyataz capsule, Viracept

Product Requested: _____

Directions for Use: _____

Non-Preferred Criteria for Approval at <i>least ONE</i> of the following criteria (1-9) must be met:			Yes	No
<p>1. Trial/Failure of Preferred. Has the patient tried and failed at least one preferred agent within the same PDL class at an appropriate dose and duration?</p> <p>Drug/Dose: _____ Reason for Failure: _____</p> <p>Treatment Dates: _____</p>	<input type="checkbox"/>	<input type="checkbox"/>		
<p>2. Cannot utilize Preferred. Has the provider submitted appropriate clinical rationale for prescribing the non-preferred product over a preferred option within the same PDL class?</p> <p>Rationale: _____</p>	<input type="checkbox"/>	<input type="checkbox"/>		
<p>3. Continuation (from previous coverage). Has the patient been treated with the requested non-preferred drug at a consistent dosage for at least 60 days in the most recent 90 days with clinical rationale to support why preferred products cannot be used? (<i>chart notes required</i>)</p> <p>Dates of Therapy: _____</p> <p>Details of Therapy: _____</p>	<input type="checkbox"/>	<input type="checkbox"/>		
<p>4. Brand required (when generic is mandated). Has the provider submitted appropriate clinical rationale for dispensing the brand name medication instead of the generic?</p> <p>Rationale: _____</p>	<input type="checkbox"/>	<input type="checkbox"/>		
<p>5. Combination product (when single-entity products available). Has the patient tried and failed individual agents in the combination product OR tried and failed a preferred agent in each of the combination product's therapeutic drug classes?</p> <p>Drug/Dose: _____ Reason for Failure: _____</p> <p>Drug/Dose: _____ Reason for Failure: _____</p> <p>Rationale: _____</p>	<input type="checkbox"/>	<input type="checkbox"/>		
Limit Exceptions - Dose, Age, Quantity, and Indication (Off-label) Limit Exception Criteria for Approval				
<p>6. Quantity/Dose Limits. Has the patient failed to achieve an adequate response within Medicaid's quantity/dose limit?</p> <p>Drug/Dose: _____ Reason for Failure: _____</p>	<input type="checkbox"/>	<input type="checkbox"/>		
<p>7. Age Limit. Has the provider submitted appropriate clinical rationale for prescribing medication outside Medicaid's age limit?</p> <p>Rationale: _____</p>	<input type="checkbox"/>	<input type="checkbox"/>		
<p>8. Off-Label Indication. Has the provider submitted supporting documentation required for any off-label indications, which includes at least one (1) major multi-site study or three (3) smaller studies published in JAMA, NEJM, Lancet or other peer review specialty medical journals within the most recent five (5) years? Supporting documentation must be included. Compendia use must be recommended by generally accepted compendia such as American</p>	<input type="checkbox"/>	<input type="checkbox"/>		

hospital Formulary Service Drug Information (AHFS), United States Pharmacopeia-Drug Information (USP-DI), and the DRUGDEX Information System.		
9. Other Details: _____	<input type="checkbox"/>	<input type="checkbox"/>
Reauthorization		
1. Has the provider submitted an updated letter with medical justification and updated chart notes demonstrating positive clinical response?	<input type="checkbox"/>	<input type="checkbox"/>
PRESCRIBER CERTIFICATION		
I hereby certify this treatment is indicated, necessary and meets the guidelines for use.		
Physician's Signature:	Date:	

Initial Authorization: Up to six (6) months

Reauthorization: Up to one (1) year

**** Failure to submit clinical documentation to support this request will result in a dismissal of the request.****

Policy: PHARM-HYB-172

Origination Date: 01/01/2026

Reviewed/Revised Date:

Next Review Date:

Current Effective Date: 01/01/2026

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.